Biologics & Biosimilar


Biologics are medicines made from living cells through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Euro Biosimilars is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA. Under U.S. law, a bio similar is approved based on a showing that it is “highly similar” to an FDA-approved biological product, known as a reference product. It may not have any clinically meaningful differences in terms of safety and effectiveness from the reference product.


  • Pharmaceutical Care Models
  • Advances in Pharmacoepidemiology & Drug Safety

Related Conference of Biologics & Biosimilar

September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 14-15, 2026

5th Global Summit on Pharmaceutical Research

Paris, France
January 26-27, 2027

22nd Annual Meet on Pharmaceutical Sciences

Paris, France
February 15-16, 2027

23rd Annual Congress on Pharmacology and Toxicology

Paris, France
April 08-09, 2027

21st World Drug Delivery Summit

Vienna, Austria
April 27-28, 2027

10th European Biopharma Congress

Paris, France
April 27-28, 2027

19th World Drug Delivery Summit

Paris, France

Biologics & Biosimilar Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in